Brazil moves cannabidiol from prohibition to special control

In January 2015 Brazil’s health regulator, Anvisa, changed the classification of cannabidiol, or CBD. RDC 3, dated 26 January, added the compound to List C1 of substances subject to special control.

Anvisa later described this as removing CBD from the prohibited-substances list and placing it among controlled substances. The distinction concerned a compound obtained from cannabis; it did not remove the cannabis plant from prohibition.

A regulatory distinction

Article 2 of the resolution names cannabidiol in the additions to List C1. Article 3 makes the resolution effective upon publication. The text updates the controlled-substances framework established under Ordinance 344 of 1998.

Being controlled was different from being freely available. Reclassification did not itself register a medicine, create ordinary retail access to cannabis flower or authorise home cultivation. Product registration and import procedures remained separate regulatory questions.

Patients in the public debate

Historian Jean Marcel Carvalho França places the January change after a discussion of Brazilian media coverage of patients and families seeking cannabis-derived products. In his account, stories of difficulty obtaining treatment helped move the public debate beyond the older figure of the deviant cannabis user.

That is a history of how arguments were presented. It does not establish the effectiveness of every product described in those reports or make their individual experiences clinical evidence.

Before the pharmacy framework

The 2019 framework for cannabis products in pharmacies was a later measure with its own authorisation requirements. The 2015 reclassification belongs to the earlier history of distinguishing CBD from the broader prohibition, rather than the creation of a general cannabis market.^[1][2][3]